In yesterday’s Wall Street session, Mangoceuticals Inc (NASDAQ:MGRX) shares traded at $0.46, down -10.73% from the previous session.
MGRX stock price is now 89.33% away from the 50-day moving average and -13.23% away from the 200-day moving average. The market capitalization of the company currently stands at $11.42M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
A total of 41.39% of the company’s stock is owned by insiders.
During the past 12 months, Mangoceuticals Inc has had a low of $0.14 and a high of $2.38. The fifty day moving average price for MGRX is $0.24894 and a two-hundred day moving average price translates $0.52561 for the stock.
The latest earnings results from Mangoceuticals Inc (NASDAQ: MGRX) was released for 2024-03-31. The net profit margin was -1067.52% and return on equity was -630.54% for MGRX. The company reported revenue of $0.21 million for the quarter, compared to $0.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 111.88 percent.
Mangoceuticals Inc(MGRX) Company Profile
Mangoceuticals, Inc. develops, markets, and sells various men’s wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
